+1-650-457-5617meetings@svicenter.com
+1-650-457-5617
meetings@svicenter.com

Visit Theravance Biopharma

Developer of biopharmaceutical drugs created for improving the lives of patients suffering from serious illness

Select Meeting Details
Theravance Biopharma

Extra services

We will confirm the details of your meeting after it is accepted by the host company

Developer of biopharmaceutical drugs created for improving the lives of patients suffering from serious illness. The company's drugs include small-molecule and antibiotics, enabling patients to combat respiratory, central nervous system or pain, gastrointestinal disorders and infectious disease in a systematic manner.

Year Founded
2013
Employees
340
RevenueTTM 3Q2018
$49.2 M
General Information
  • Website

    http://theravance.com

  • Business Status

    Profitable

  • Ownership Status

    Publicly Held

  • Financing Status

    Corporation

Theravance Biopharma Primary Industry Sector / Group / Code
Theravance Biopharma Status

The company (NASDAQ: TBPH) reached a definitive agreement to be acquired by Mylan (NASDAQ: MYL) for $265 million on February 2, 2015. Subsequently the deal was cancelled. Previously, the company underwent an initial public offering on NASDAQ stock exchange under the ticer symbol of TBPH on May 16, 2014. The company was spun out off from Theravance Inc.

Theravance Biopharma Metrics
Growth Rate
SimilarWeb Unique Visitors
Majestic Referring Domains
Headquarters
Get Directions
  • HQ Address Line 1
    901 Gateway Boulevard
  • HQ Address Line 2
    George Town, PO Box 309
  • HQ City
    San Francisco
  • HQ State/Province
    California
  • HQ Post Code
    94080
  • HQ Country
    United States
Theravance Biopharma's Keywords
bacteria infectionrespiratory disease
mood_bad
  • No comments yet.
    • chat
    Add a review

    Leave a Reply ·

    mood_bad
  • Feed is empty.

    • You May Also Be Interested In